Description: UCI BioSci M121 covers the following topics: Antibodies, antigens, antigen-antibody reactions, cells and tissues of lymphoreticular and hematopoietic systems, and individual and collective components of cell-mediated and humoral immune response.
All right, we can get started.
There's a fellow with a San Francisco Giants hat over there.
It's not allowed in my class.
There's a guy with a Dodgers cap behind you,
so watch your back.
It's actually not that funny because there's been violence at
both stadiums the last couple of years with this Dodgers-Giants.
Yeah. Okay. Well, today we're going to finish
the lectures before the midterm and leave 10 minutes at the end to
talk about whatever questions you have about lectures 1-10.
So let's get straight to it.
I had mentioned during the lecture on VDJ recombination that
the process of junctional diversity that occurs during VDJ joining,
causes a problem in that two out of three times,
you end up with nucleotides that make the gene out of frame.
So you can't make a functional protein.
In order for B cells to survive,
you need a productive gene rearrangement at
the heavy chain locus and the light chain locus.
So if the chances of any one gene rearrangement being successful is one in
three because the reading frames are there's three nucleotides per codon,
there has to be a mechanism to deal with this.
But it doesn't always work and if you have something called a non-productive
rearrangement at both the heavy chain loci,
both chromosomes or if you can't productively rearrange the light chains,
the B cell will die.
So developing B cells are programmed to die by apoptosis if they
cannot generate productive rearrangements that lead to an in-frame joining,
leading to production of a protein on the surface of the cell.
So let's go stage by stage in B cell development.
If you remember the earliest stage of
committed B cells called the early pro B cell stage.
At this stage, you actually have
both chromosomes for the heavy chain active undergoing D and J rearrangements.
There's no screening at this point for productive rearrangements
because no proteins are being produced anyway.
That doesn't happen until the later stage.
So all you need to know about the early pro B cell stage is
that you get a D and J rearrangement on each chromosome.
That allows you to transition to the late pro B cell stage.
Here, one of the chromosomes stops rearranging and the other chromosome,
you have a heavy chain rearrangement where
a V-segment is chosen to rearrange to the D-J segment.
Two, there's two possible outcomes of that that can lead to
productive rearrangement that's in-frame or a
non-productive or sometimes written unproductive rearrangement.
If you have an unproductive rearrangement or non-productive rearrangement,
then you try to rearrange the second chromosome.
That can also have two outcomes.
It can rearrange productively or it can fail to rearrange productively.
If either of the first or the second chromosome has a productive rearrangement,
the cell receives a survival signal.
But if you fail both times,
the cell will die by apoptosis,
which is the default pathway.
Overall, I won't go through the math,
but you end up with about 50 percent of
late pro-B cells generating a productive heavy chain rearrangement,
and go on and survive,
and about 50 percent will die.
Now, it says in the notes that you can't do a further rearrangement if they don't
work because you've lost the RSS sequences upstream of the D-segment here.
What that means will become apparent later when we talk about
J-segment rearrangements or V-J segment rearrangements in the light chain.
The next stage of B-cell development is called the large pre-B cell stage.
At this stage, because you've had a functional rearrangement of the heavy chain,
you now have a heavy chain come to the surface of the cell,
but no light chains have been produced yet.
In order for this to get to the surface,
it is accompanied by two proteins that together form what's called the surrogate light chain.
This surrogate light chain is composed of these proteins known as Lambda-5 and V-pre-B.
Two other proteins are also involved in
stabilizing the heavy chain and directing it to the cell surface,
and these are known as Ig Alpha and Beta.
I believe I referred to them earlier on as they're involved in signal transduction.
It's not clear from this diagram,
but they have much longer cytoplasmic tails,
and so they interact with intracellular proteins to direct B-cell signaling.
In the notes, it mentions that these are analogous to some other proteins in T-cells.
We haven't actually gotten to there yet because I changed the order of the lectures this year.
So just hold off on that,
and when we talk about T-cell receptors and their signaling,
we will mention and come back to how these Ig Alpha and Beta chains work.
Now, having this pre-B-cell receptor as it's called with a heavy chain,
surrogate light chain, and Ig Alpha Beta on the surface is really important
because it sends a signal to the cell that a functional heavy chain has been produced,
and that has two outcomes.
One is that the cell is instructed to proliferate and divide like crazy,
and you get about 100 daughter cells from
one large pre-B-cell that has a functional heavy chain on the surface.
The second is that it signals the cell to stop
rearranging if there is another heavy chain locus.
So if you go back to this slide,
if the first rearrangement is successful and you have
a heavy chain on the surface as part of the pre-B-cell receptor,
the signal allows it to survive,
become a large pre-B-cell,
and prevents rearrangement of the second chromosome, the second allele,
and that is the basis for the term that I
defined a few lectures ago known as allelic exclusion.
Now, signaling through the pre-B-cell receptor
involves a number of cytoplasmic proteins.
One of them that's essential is known as BTK,
and that stands for Bruton's tyrosine kinase after the Dr. Bruton who discovered it.
Humans who lack BTK cannot make mature B-cells or even immature B-cells.
They're stuck at this early probe to pre-B-cell transition,
and they have a disease known as X-linked agammaglobulinemia.
That's a long name, but you can abbreviate it XLA.
It's a rare disease, but it's not that uncommon,
and it's X-linked, so it occurs mainly in boys.
These boys have very few mature B-cells.
They make very little antibody,
which is why it's called agammaglobulinemia,
no gamma globulins, IgGs.
You signal the cell to survive,
you signal for allelic exclusion,
and you signal for proliferation.
Now you have about 100 daughter cells from each cell that has a functional heavy chain.
Each of those will undergo light chain rearrangement in a separate and random fashion.
So you can have up to 100 or so different B-cell clones,
each with the same heavy chain and different light chains.
So let's just go back to a figure I showed last time, figure 6-4.
I don't think this is in the version that I posted on the website of today's lecture,
but it just reminds you again,
the early pro-B-cell is where D-J rearrangements occur.
The late pro-B-cell, V-to-D-J rearrangements.
If you get a functional heavy chain,
then you reach the large pre-B-cell stage where you have this V-D-J rearrangement.
The light chain genes are not rearranged yet,
the heavy chain is made.
At the end of this proliferation process,
you transition to the small pre-B-cell stage.
The pre-B-cell receptor is no longer on the surface.
The mu chain, the heavy chain is now found mainly in the endoplasmic reticulum,
and that's in part because the surrogate light chains are no longer expressed.
It's at this stage that you have the light chain rearrangements occurring.
So the small pre-B-cell,
it's just shown as pre-B-cell here,
but you can write in, if you want,
small pre-B-cell is where the light chain rearrangement occurs.
This also goes sequentially.
Remember, there's two isotypes,
kappa and lambda,
and there's two alleles for each,
and they're not all rearranging at the same time.
You go one chromosome at a time,
and in general, one of the kappa loci rearranges first.
Again, the outcomes are shown here by these plus minus diagrams.
If the first rearrangement is successful and productive,
you stop further rearrangements at other light chain loci,
and you express IgM with a kappa chain diagram here in green.
If that is not successful,
you try the other chromosome for kappa,
and that gives you a chance to make a kappa light chain.
If either of these is successful,
then one of the lambda loci is used to try a rearrangement.
If that works, then you make a lambda light chain.
If that doesn't work, unproductive,
then the second lambda light chain chromosome is used,
and then you still have a chance to make a lambda light chain.
If none of these work, then the cell will die by apoptosis.
Now, there's something different about light chain rearrangement,
and that's shown in figure 6-9, which is that at each
of those four loci, the two kappa and the two lambda,
the arrangement allows you to make successive attempts
at rearrangement, so if the first one's not successful,
you can try, try again, and that is apparent if you look
at the arrangement of the V segments and the J segments.
In this example, V kappa 1 is the first one selected
to J kappa 2.
If that's a nonfunctional or nonproductive rearrangement
so that no, it's out of frame and no light chain is produced,
you still can use an upstream V kappa
and a downstream J kappa to try a second time.
A second VJ recombination occurs.
If that was productive, you would make a kappa light chain
and stop further rearrangements,
but in this example, it's nonproductive.
You still have further upstream V kappas
and one more downstream J kappa that you can try,
so there's multiple chances to make a successful kappa
or lambda rearrangement at each of these loci.
Now, if it happens by random chance
that at this locus you chose the first V kappa
and the last J kappa as the first rearrangement,
you couldn't do a second one because all
of the intervening DNA would be lost.
That does sometimes happen, but more often, some other V kappa
and one of the other J kappas is chosen randomly first
and so you have chance to use another one
if you can't make a protein if you're out of frame,
but overall, the presence of 4 instead of 2 loci, there's 2
for the heavy chain, but 4 for light chain and this ability
to do successive rearrangements means
that light chain rearrangement almost always results
in a functional protein and it's estimated that at least 85%
of small pre-B cells are successful
in making a light chain eventually and the last thing
to remember is that kappa
and lambda isotypes have no functional differences.
I mean, the actual, the regions, the CDR loops
that are contributed will be slightly different,
but in terms of their constant regions and ability to pair
with IgM heavy chains or other isotypes,
they have no functional differences,
so they're equivalent.
It doesn't matter which kappa locus or lambda locus you use.
If you make a functional protein,
it can work in an antibody.
So coming back to this figure, you make a kappa light chain
or a lambda light chain, now you have transitioned past the pre-B
cell stage and you're what's known as an immature B cell.
It sounds like you should be mature,
but you still have a ways to go.
This is the stage at which selection and removal
of self-reactive cells occurs before you can become a
mature B cell.
At the immature B cell stage, you express IgM on the surface,
you can see the blue heavy chains here, but very few
of these will survive to become mature B cells
because many will be self-reactive.
Any questions so far?
Yeah?
Yeah, there's technically no difference,
but in humans you always have more kappa
because they tend to rearrange first.
There's some mammals where it's the reverse,
there's more lambda, but all mammalian species
that we've looked at have two different light chain isotypes
that are equivalent and it probably just, it's important
to have two so that you have more chance
to make mature B cells without failing rearrangement.
So let's talk for a minute about allelic exclusion,
why is it important?
You understand the concept
that you can only make one heavy chain,
you can only make one light chain
because once you get a heavy chain on the surface,
you prevent further rearrangements,
once you get a light chain,
you prevent further rearrangements,
but why is it important?
It's important because that leaves you with all the BCR
on the surface, all the surface Ig has a single specificity.
Homogeneous B cell receptors with high validity binding,
if you did not have allelic exclusion in this example here,
let's say the cell's making two different heavy chains,
they're not showing two different light chains,
but just to make it simple, two different heavy chains,
some will have two of the blue ones, some will have two
of the green ones, some will have one of each,
when you encounter an antigen,
half of the antibodies won't be able to bind at all,
and or a third of them or so won't be able to bind at all,
but some of them will have, will be able to bind with one arm
and not the other, so you don't get as high avidity,
and only some of the BCR will have both arms engaged.
So it's important that you have,
each B cell has just one heavy chain and one light chain
to increase the avidity of binding
when you do encounter an antigen.
So then the question is how does this work,
how does allelic exclusion work?
Now you can go to figure 612,
and this basically shows you all our favorite stages here,
early Pro B, late Pro B, etcetera, and a number
of proteins down here, their function, and in orange,
the stages at where they're expressed.
So we're not going to talk about all of these,
I'll just show you the ones we're interested in here.
We'll start with RAG1 and RAG2, as you know,
these are only expressed in developing B and T cells,
so it's lymphoid specific recombinase,
but it's even more complicated than that, because RAG1
and RAG2 are expressed early when you need
to rearrange heavy chains, and then turned off
at the large Pre-B cell stage.
You can see, so that is, that's the mechanism
for allelic exclusion.
When the Pre-B cell receptor is expressed, a signal is sent
to the cell to shut off RAG1 and RAG2.
If there's no RAG1 and RAG2, you can't rearrange the other locus.
And it doesn't come back again until the small Pre-B cell stage
when it's time to rearrange the light chain.
Now you'll notice it stays on in the immature B cell stage,
and that will be important when we talk
about selection later on.
You'll notice other genes we've talked about that are expressed
at different stages, so IG alpha and beta come on really early,
they need to be around to produce a Pre-B cell receptor.
The surrogate light chain proteins, lambda 5
and V Pre-B, also come on at the same time as IG alpha and beta,
but they're turned off at the small Pre-B cell stage,
and now the new heavy chain goes back to inside the cell,
waiting for a real light chain to be produced.
So what we're left with is a system of checkpoints that's
shown in figure 611, and there are two
that you need to understand.
These checkpoints are important to ensure
that B cells survive only if a functional heavy
and light chain are produced.
At the early Pro-B cell stage is where there's commitment
to this lineage, if you get heavy chain rearrangement,
the surrogate light chain components can come
to the surface as part of the Pre-B cell receptor,
and that allows the cell to survive, divide,
and eventually undergo light chain rearrangement.
If no heavy chain is produced
because of unproductive rearrangements,
the surrogate light chains stay in the cytoplasm.
There's no Pre-B cell receptor produced, no survival signal,
the cell dies by apoptosis.
So this is the first checkpoint.
It selects for functional heavy chains.
Later, light chain rearrangement occurs.
There's no more surrogate light chain.
The heavy chain is just waiting for a real light chain.
If a light chain is produced, a B cell receptor is made.
It would be nice if they color-coded these
with different light chains, but this is an IgM molecule
with a Kappa or Lambda light chain, and Ig Alpha
and Beta here, that signals the cell to move
on to immature B cell stage
and undergo selection for self-reactivity.
If no light chains are produced, which is rare,
but if it does happen, the heavy chains cannot come
to the surface, you do not get that survival signal,
and the cell dies by apoptosis.
So the second checkpoint selects for functional light chains.
If you survive both of those, you have your immature B cell
with IgM on the surface.
And figure 616 really just summarizes everything we've seen
already, putting it all together,
and it's just something that you can use for your study.
Any questions?
So the question is how these get to the surface.
So as with any proteins destined to be on the cell surface,
they go through, they start in the ER, then they go
to the Golgi, and then the trans-Golgi network,
and then the vesicles that bring them to the surface.
But for reasons that are too complicated to explain,
they only complete that process
if all the components are there together,
including the surrogate light chains here with a heavy chain,
or at this stage, the real light chains
with a heavy chain and IgAlpha or Beta.
Any of them are missing.
If you knock out surrogate light chains here, or IgAlpha and Beta,
you don't get surface expression of the pre-B cell receptor
or later the B cell receptor.
Okay, so we'll take a short break today to talk
about me, your teacher.
I often used to hear from students that they were
interested to know more about their professors,
and so what is it that I've done that qualifies me to stand
up here and tell you about immunology?
Why am I being paid the big bucks
to be a professor at UC Irvine?
So I will tell you how I got here and a little bit
about what we're doing now, and I'll try not
to take too much time away from the review session.
I told you that BTK is required for B cell development,
and the humans that don't have BTK don't make B cells.
So mice that don't have BTK also have a problem making B cells,
and I became interested in B cell development as a postdoc
working in a lab at Harvard, and the way I got into this is
because the lab I was working at had identified
and discovered an enzyme known as PI3K, which is highly active
in cancer cells and in any dividing cell responding
to growth factor, and the way it works is here's a growth
factor receptor, no growth factor, no ligand around.
PI3 kinase is this dimeric protein, P85, P110.
It's in the cytoplasm.
Nothing's happening.
The ligand comes along, a growth factor,
gets some phosphorylation event shown here as P,
and now the P85 subunit can be recruited to this receptor,
and this P110 subunit is an enzyme that converts a lipid
in the membrane PIP2 to something called PIP3.
So it has three phosphates on an acetyl lipid, and that leads
to recruitment of other proteins to the membrane
that can then transmit signals to the cell,
and this is an evolutionarily conserved process.
You find it in yeast.
You find it in all eukaryotes.
So it turns out one of, there was some biochemical evidence
that BTK was one of these effector proteins that is
brought to the membrane in B cells
when PI3 kinase is activated,
but it hadn't really been studied in great detail,
and I made mice that lacked the P85 gene,
so they can't respond to ligand, in this case antigen binding
to B cell receptor, and what we found was, and here's the paper.
This is in the journal Science,
that there was impaired B cell development and proliferation
and reduced antibodies.
It's not in the title, but in the absence
of this phosphatidyl 3 kinase P85 alpha gene,
and at the same time in the same issue,
a group from Japan found a similar mouse knockout,
and they found, they showed that immunodeficiency was similar
to a mouse known as XID mouse, and what does XID mean?
X-linked immunodeficiency.
These mice have mutations in BTK, specifically in the region
of BTK that's required for binding to PIP3.
So it's all very complicated, but the bottom line is,
we provided genetic link between PI3 kinase and BTK,
and both were involved in a signaling pathway that's
important both in mice and humans for making B cells,
and later on, another group knocked out P110, a P110 gene,
and they found very similar defects
in B cells as well as T cells, and then to my great
satisfaction, or I guess, I'm not happy
that there's a human patient with this disease,
but about 10 years later, our work in mice was validated
by the finding of a human patient who has a mutation
in the human gene for P85, and they also don't have B cells,
and they can't make antibodies.
So in the time since then, what we've been working
on in my lab is just trying to understand more
about the details of this pathway in normal B cells as well
as leukemia cells and lymphoma cells, and I'm always happy
to talk more about this outside of class time.
Actually, I do want to say one more thing,
which is that drugs targeting PI3 kinase were identified
over the last 10 years, and a drug targeting this particular
form of PI3 kinase was developed initially to try
to treat antibody-mediated diseases by suppressing B cells.
It turns out it's dramatically effective
in tumors arising from B cells.
So there's human patients who are near death
with B cell lymphomas and leukemias who have been treated
with inhibitors of this enzyme
and are now living fairly healthy lives.
So that's another exciting aspect of this signaling pathway.
Okay, back to reality and the lecture here, what you need
to learn for the midterm.
This figure, 615, begins to tell you
about classes of mature B cells.
We're skipping ahead past selection of immature B cells.
We'll come back to them in a few minutes, but I want to talk
about the two general classes of mature B cells,
and they're known as B1 cells and B2 cells.
B1 cells are produced by a different developmental pathway
and they're first produced early in fetal development,
and you can identify them by the expression
of a protein called CD5.
It's not on this slide, but CD5 in both humans
and mice is a marker for the B1 cell population.
What's interesting about them also is
that they're mainly found, the B1 cells are found
in the peritoneal and pleural cavities, basically the gut
and the lung cavities, whereas conventional cells,
which is what we'll spend most of the time
on in this class, circulate or found in blood
and secondary lymphoid organs.
And also, they have a restricted junctional diversity
and restricted B region repertoire.
So they don't have, it's not really random which B segments
that they use, and they don't have nearly
as much junctional diversity.
So they seem to be kind
of an evolutionarily conserved innate-like B cell subset
that is produced that has a limited diversity,
but those specificities tend to be useful
in combating commonly encountered pathogens
that might be in the gut or the lung cavities.
So we talk a lot in this class about innate immunity
and adaptive immunity, and B and T cells are part
of adaptive immunity, and everything else is part
of innate immunity, and dendritic cells are a bridge
between the two, but it's increasingly apparent
that within lymphocytes, B cells and T cells,
there are specialized subsets that aren't quite so diverse
in their V region repertoires or junctional diversity.
They're not so diverse in where they're found in the body.
They're localized in certain areas.
The first example is the B1 cell,
and you'll hear about others later on.
There are specialized subsets of B cells or T cells
that are somewhat innate-like
in that they don't have an unlimited repertoire,
and they're designed to fight specific commonly
encountered pathogens, and they're only
in certain locations in the body.
So that's the concept I want to get across.
This is the first of some other ones you'll learn about.
It's an innate-like lymphocyte.
It's found in a specific place, shown here.
Restricted diversity compared to the conventional cells
where it's very extensive and diverse.
The other details we won't talk about for this class,
but the concept of an innate-like B cell called a B1
cell is what I wanted to get across.
Any questions about that?
Immunology is always more complicated than you think.
I went to an immunology seminar last week
that completely changed the way I think about a topic
that we're going to talk about after the midterm.
So it's always changing.
I think what's in the book now is valid up to a point,
but it's fascinating what we don't know
and what we're learning today.
All right.
So now we're going to deal with the challenge
of self-reactive cells, and we have 10 minutes
to do this before we get on to the review session.
Now, I want to define a self-antigen first.
A self-antigen is a normal component of your cells
or your tissues or body fluids that can bind
to the surface antigen receptor.
In this case, the surface IG on B cells.
And you have hundreds, millions of these.
Any surface of a self-protein, a carbohydrate, lipid,
anything that you can generate an antibody response to,
if it's commonly, normally found
in your antibody can be considered a self-antigen.
Now, there's two types of self-antigens
that we will discuss in this lecture.
The monovalent self-antigen,
which basically has a single epitope that can be recognized
by an antibody, or a multivalent self-antigen,
which has multiple epitopes.
An example of a monovalent antigen might be a protein
in plasma, like albumin.
On the albumin surface, there's only, if you have an antibody
to albumin, and it's only, you're only going
to have one albumin molecule bound to one arm of the antibody.
You may have a second albumin molecule bound
to the other arm, but only one epitope on each.
As opposed to, let's say, the surface of a virus,
which would have multiple repeating epitopes,
and the same antibody is bound to multiple copies of that.
A multi, another example
of a monovalent self-antigen might be,
from last lecture, IL-7.
It's a cytokine secreted by bone marrow stromal cells,
and it's a monomeric protein.
If you have an antibody to it, it will bind
to a single epitope on that self-antigen.
What would be an example of a multivalent self-antigen?
Well, an example would be a self-surface adhesion molecule
on the bone marrow stromal cells,
like the VCAM1 we talked about.
There might be tens of thousands of VCAM1 molecules all
on the surface, and so a B-cell encountering
that will have many different chances,
many different B-cell receptors that can all stick
to the surface it's interacting with and be clustered together.
And as we go through the lecture,
I think this will become more clear what I mean
by monovalent versus multivalent self-antigens.
So starting with figure 617,
it just gives you the general concept for what happens
when you have reaction with a self-antigen.
If there's no reaction, you have an immature B-cell
in the bone marrow.
It does not detect any self-reactivity.
It will move to the blood in the spleen and start to recirculate,
and at that point, it will express IgD and IgM
through alternative splicing and then go around looking
for foreign antigens as a mature B-cell.
But now we're going to talk for a while
about reaction with self-antigen.
If a B-cell detects a self-antigen, in this example,
it's on the surface of the bone marrow cell,
but it could be a monovalent or soluble antigen,
then you get retention of the immature B-cell
in the bone marrow, and the problem needs to be dealt with.
One of the ways it's dealt with is just by apoptosis.
So some immature B-cells that encounter self-antigen,
particularly multivalent self-antigen
that causes a strong cross-linking response
of all the receptors on the B-cell, the immature B-cell,
it will just die by apoptosis,
and that process is known as clonal deletion.
But to save us from having so many B-cells clonally deleted,
there's a process known as receptor editing
that gives you a chance
to make a different antigen specificity
and escape from death, and this occurs
when you encounter a multivalent self-antigen.
So here's a bone marrow cell.
Let's imagine this is VCAM1 or any other receptor that's
on multiple copies on the bone marrow cell, and what happens is
that multiple different IgM molecules will recognize those.
They only show two here, but typically it might be tens
or hundreds of them, and they'll all kind of cluster together
on this surface of the immature B-cell as it interacts
with a bone marrow stromal cell, and that sends a strong signal
to the cell to either die by clonal deletion
or to do this process known as receptor editing,
and receptor editing refers to going back
to the light chain locus and trying successive rearrangements.
So remember that during light chain rearrangement
at the small pre-B-cell stage,
if you don't make a functional light chain, you can continue
to rearrange the same locus.
If you make a successful light chain but it's self-reactive
with a heavy chain, then RAG1 and RAG2 are expressed again.
I showed you before that RAG1 and RAG2 remain
on at the immature B-cell stage,
and that expression is preserved if you're self-reactive,
and that allows additional V-segments
and J-segments to be joined together.
So immature B-cell continues to rearrange light chain genes
and now can make a new light chain,
and therefore the IgM has a different specificity.
The heavy chain hasn't changed,
but the light chain is slightly different now.
Might have a different V-segment, different J-segment,
different junctional diversity, and all that.
Okay? So you have a different specificity.
If the new receptor is not self-reactive,
the B-cell can leave the bone marrow just
like the ones we saw earlier.
If the new self-reactor is still self-reactive, you can continue
to rearrange light chain genes at that locus or at other ones
that have not been used yet.
So after receptor editing, you can sometimes use the second
kappa or the lambda light chains, eventually leading
to expression of a light chain that, again,
might be non-self-reactive and can leave the bone marrow.
If it continues to happen, and no matter what you do,
you're still self-reactive
and no further rearrangements are possible,
then the immature B-cell will undergo apoptosis and you arrive
at that outcome of clonal deletion.
And it's thought that clonal deletion really only happens
when you failed receptor editing.
And because you have all these light chains and success
rearrangements, receptor editing often can rescue the immature
B-cell from death.
Of course, if the heavy chain contributes a lot
of binding energy for the self-antigen,
it might not matter what light chain you produce.
It may be inescapable from dying
from reaction with the self-antigen.
Does that make sense?
What about a monovalent self-antigen?
They call it a univalent self-antigen here.
And it's useful to think about these as soluble proteins
or other types of antigens that are basically all
around the cell in three dimensions.
So even if a lot of them are around,
like albumin is very common in the blood
and in the bone marrow, they're going to coat the surface
of the B-cell by binding to all these B-cell receptors,
but they're never going to cluster any
of the B-cells in one place.
That's different than if an immature B-cell contacts
at a bone marrow stromal cell, all the B-cell receptors are
going to sort of cluster at the surface of contact.
That sends a strong signal to initiate receptor editing.
If you have a soluble univalent self-antigen,
even if it's very abundant, you're just going to sort
of coat the surface of the cell without any clustering.
It produces a weak signal, not a very strong signal,
and that causes a different outcome,
which is known as anergy.
And the B-cell is known as an anergic B-cell,
and it's basically the opposite of energy.
It's a cell without energy.
It's anergic.
They're not deleted.
They don't undergo receptor editing.
And they actually can leave the bone marrow,
and enter the peripheral circulation,
but they tend to die very quickly.
So in the end, it has the same outcome as clonal deletion.
You produce a short-lived B-cell that eventually dies.
And there's some other properties
in that IgM expression goes way down on the surface.
Tends to be retained inside the cell, and you express IgD
on the surface, but IgD doesn't signal very strongly.
So anergic B-cells can survive for a little bit.
They have different properties than regular mature B-cells,
but in the end, the outcome is the same as clonal deletion.
This B-cell that's self-reactive cannot survive and become part
of the repertoire that fights infection.
One last thing I want to say about this is the general
concept in signal transduction that clustering
of receptors produces a strong signal, and just tickling
of a little receptor here or there on the surface
of the cell produces a weaker signal, is very common,
and is valid in a lot of the immunology that we'll talk about.
We saw it already with phagocytosis.
A lot of FC receptors have to engage IgG on the surface
of a pathogen in order to produce a strong signal to lead
to engulfment of the pathogen.
So clustering of receptors is what's required
to send a strong signal.
So let's go back to this figure.
What if you make an immature B-cell that reacts
with a protein or some antigen that's not found
in the bone marrow?
Let's say it's found in some specific tissue.
It could be self-reactive, right?
It's just not encountering its self-antigen at the time
of selection in the bone marrow.
That is known as immunological ignorance.
So you do have some self-reactive immature B-cells,
and nothing happens to them in the bone marrow,
and that could be
because the self-antigen is not accessible during this
education process, or it could be because the affinity is
so weak that it doesn't produce a strong enough signal,
whether multivalent or monovalent.
Now, it's important that you don't delete every B-cell
because you have to have some repertoire.
So that's one reason why some potentially self-reactive
B-cells escape, but I also mentioned last time
that there are additional mechanisms
that preserve tolerance in the periphery known
as peripheral tolerance, and one of them is that for a B-cell
to encounter antigen and then become a plasma cell
or a memory cell, it needs help from T-cells.
So even if it encounters an antigen somewhere else
that it wasn't in the bone marrow, if there's no T-cells
to help it, it will essentially end up in the same place.
It will undergo this process of energy and eventually die,
and we'll learn
about peripheral tolerance mechanisms later on.
Nevertheless, the potentially self-reactive B-cells
that escape the bone marrow can be the seeds
of autoimmunity later on, and in diseases like lupus
and other antibody-driven autoimmune diseases,
one of the most common types of antibodies are
to double-stranded DNA or other nuclear antigens
that are not found in the healthy bone marrow
where all the cells are alive and any dying cell is taken
up by macrophages.
Lupus patients tend to have lots of nuclear material
around because their cells have defects and apoptosis.
Then you can get these anti-DNA and anti-RNA
or ribonucleoprotein antibodies.
This is outside the scope of today's lecture,
but just tells you just to keep in mind that central tolerance
in the bone marrow for B-cells and the thymus
for T-cells eliminates most of your self-reactivity,
but not all of it, and that is why you have the potential
for autoimmune disease later on.
Okay, so what if you're ignorant
or if there is no self-antigen and you come out, again,
I just want to remind you,
this cell is now called an amature B-cell to distinguish
from the immature B-cell where selection occurs.
B-cell that's recirculating is a mature B-cell.
It expresses both IgM and IgD on the surface,
makes a single long mRNA, and through use
of different RNA processing mechanisms can,
the same mRNA that's produced can,
the same initial transcript that's produced can be spliced
into forms that produce IgM heavy chains
or IgD heavy chains, and until these encounter antigens,
they're known as naive B-cells.
Okay, I have a few more slides that I decided to skip
and bring back in the lecture that goes with Chapter 9,
Part 1, so that we can have some time
to do a little review session here.
Any questions about the last bit of today's lecture?
Okay, so I have all my lectures here.
I'll put them all on the desktop.
Questions?
Yes? Yeah, so how does chemokine binding lead to a change
in affinity of LFA1?
It's called inside-out signaling and phosphorylation events
and other processes lead to change in the cytoskeletal
proteins that position LFA1 and that changes its conformation
so that it has high affinity for ICAM-1,
but we didn't talk about that, so ICAM-1 does not, yeah.
Next. Okay, go ahead.
Okay, so here we go.
You will learn about this after the midterm,
but just to let you know, most of the time
when a macrophage engulfs a bacteria, it can degrade it,
but there are certain macrophages
or certain pathogens like tuberculosis
that are perfectly happy living in the vesicles
and in the phagosomes and phagoslicosomes.
So what the helper T cell does by providing interferon gamma
and other cytokines, it makes the macrophage
into a super killer macrophage that does a better job
of eradicating the intracellular or vesicular pathogen.
In the back.
Okay, so we need to go to Lecture 7, I believe.
Because the antibody, the antigen binding surface is
contributed by both the light chain and the heavy chain,
so you're always going to, I mean, the V segments
for heavy chain are different than the V segments
for light chain.
There are different chromosomes, different V segments,
different J segments.
So by definition, the V, D, and J segments
for the heavy chain will be different than the ones
for the light chain, but the CDR 1, 2, and 3 loops
of the heavy chain together with the CDR 1, 2, and 3 loops
of the light chain are what produce the antigen binding
site, which you see in Lecture 6 in pictures like this.
So they have them color-coded here.
The red is the antigen, the yellow, green, blue, purple,
these are the different CDR 3 loops.
And so, of course, the heavy and light chain are going
to contribute separately to that.
Does that answer the question?
Well, in this, yeah, so remember, though,
you have this army of more than a billion different B cells,
and only a few of them will bind to a particular antigen,
and those are selected by the antigen to clonally expand.
So the vast majority of the heavy
and light chain pairs you make are not going
to bind the antigen.
So by definition, the B cell
that responds has a heavy and light chain
that have affinity for that antigen.
The VDJ recombination is random.
It occurs before antigen is encountered.
The goal is to produce a diverse army of B cells, and then those
that are useful will be selected to expand.
Yeah? The C region genes are all together on the same chromosome.
So, and the next one, yeah, right.
So the mu and delta exons are closest to VDJ.
This is in the immature and mature cells.
You get transcript to here.
In the immature cells, only, the only splicing event
that happens makes IgM.
Mature cells make both IgM and IgD,
but all the other constant region exons are available
on the same chromosome later for class-switch recombination,
which is a completely different process than VDJ recombination.
All right.
Somebody else?
Yeah? Okay.
So a multivalent antigen is one that there are multiple copies
of the epitope that are on the surface of a cell
or on the surface of an extracellular matrix
that are basically fixed in space in two dimensions almost.
So that, and this is a good question, and a lot
of people get confused by this.
So imagine a cell as a round sphere,
and they're only showing, you know,
four B-cell receptors here, but there's tens of thousands
of them on the surface of, let's say, a balloon.
If the balloon bumps into another cell, the only,
the multivalent antigens, let's say it's VCAM
or something else on the stromal cell,
all the B-cell receptors will accumulate there at the end
of the balloon or at the end of the sphere,
and they'll all be right next to each other.
Because there's multivalent many copies
of the epitope all right next to each other at kind of the surface
where the B-cell's touching, you get the congregation
or clustering of those B-cells, B-cell receptors.
If, on the other hand, it's monovalent,
there's only one epitope, and there's multiple copies
of the antigen, but they're all in three dimensions,
like in the blood or in the lymph.
So it's, they're all around the cell, all around the balloon.
Even if they're all covered all over the place,
and the B-cell receptors are diffusing in the membrane,
none of them are going to bump into each other
and produce this clustering effect.
So multivalent antigens, by nature, are all kind
of together, fixed in space, and that leads to accumulation
of the B-cell receptors together at that contact point.
Still have a couple minutes?
Yep. Okay.
Now, you don't need to know the details of the hat medium
for selecting, except that myeloma cells can't survive
in it, and other cells can't.
Anybody clustering on the cell surface
of an immature B-cell causes receptor editing.
On the, anybody clustering on the surface
of a mature B-cell is important for activating the B-cell.
On an immature cell, at least apoptosis.
There was one back there?
Okay.
Does IgM serve no other purpose besides recognizing
self-antigen?
Yes, on the mature B-cell, it's important
for recognizing foreign antigens.
Yeah, the inside of the cell changes
so that the same signal is interpreted differently.
In the immature cell, it's interpreted as a death signal
or a receptor editing signal.
In the mature cell, it's interpreted by the cell
as a proliferation and clonal expansion signal.
Yeah? Yeah, so if you have a pathogen that gets
into your bone marrow, will that cause clonal deletion
and tolerance?
Yes, but you should probably also already have some mature
B-cells elsewhere in the body that could be dealing with it.
Okay, if you have other questions, I encourage you
to use the message board.
It's been underutilized.
I'll keep an eye on it over the weekend.
Don't send me emails at 2 in the morning on Sunday night,
expecting an answer.
I will see you here on Monday, and good luck on the midterm.